Full-Time

Senior Specialist Regulatory Key Initiatives

Updated on 7/21/2026

Viatris

Viatris

10,001+ employees

Global pharma selling generics and biosimilars

No salary listed

Dublin, Ireland

In Person

On-site role based in Dublin, Ireland.

Category
Legal & Compliance (1)
Required Skills
Word/Pages/Docs
Data Governance
Excel/Numbers/Sheets

Get referred to Viatris

Find people who can refer or advise you

Requirements
  • Bachelor’s degree (or equivalent) with pharmaceutical industry experience, preferably in Regulatory Affairs or Regulatory Operations
  • Strong knowledge of EU regulatory frameworks, including EMA procedures, XEVMPD, and working knowledge of IDMP and SPOR
  • Experience with Regulatory Information Management (RIM) systems and understanding of the eCTD structure
  • Ability to interpret complex regulatory and technical documentation, including labelling (e.g. SmPC) and eCTD modules
  • Strong organisational skills, with the ability to manage multiple projects and deadlines simultaneously
  • Comfort working with complex systems and IT tools, including document and data management platforms
  • Excellent attention to detail and a proactive, continuous learning mindset
  • Strong collaboration and communication skills, with the ability to work cross-functionally and present complex information clearly
  • Proficiency in Microsoft Word and Excel; experience with document management systems is advantageous
Responsibilities
  • Monitor and interpret global regulatory initiatives, with a strong focus on EU regulations (e.g. IDMP, eCTD 4.0, SPOR), ensuring the organisation remains compliant and informed
  • Lead cross-functional collaboration to identify data owners, improve data governance, and support IDMP implementation
  • Act as a subject matter expert (SME) on regulatory data, partnering with stakeholders to define, source, and maintain high-quality data, including establishing QC processes
  • Drive data management and enrichment activities, including populating IDMP templates and supporting internal RIM systems and external databases (e.g. EMA PMS)
  • Identify, prioritise, and resolve data discrepancies, proposing solutions and ensuring visibility through appropriate escalation
  • Develop and improve business processes and SOPs, ensuring clear ownership (RACI), efficient workflows, and regulatory compliance
  • Support system and process improvements within RIM and related platforms, aligning with evolving regulatory requirements
  • Contribute to change management and training initiatives, supporting adoption of new processes, systems, and regulatory standards
  • Collaborate with Regulatory Operations, Master Data, and other teams to ensure data alignment, consistency, and integration across systems

Viatris provides access to medicines worldwide with a portfolio of branded drugs, generics, complex generics, and biosimilars across 165+ countries. Medicines are manufactured and distributed through its global supply chain and commercial network, serving cardiovascular, infectious diseases, immunology, and oncology. It leverages the legacy of Mylan and Upjohn to grow through both expanding its existing products and pursuing partnerships and acquisitions, driven by its broad portfolio and international reach. The goal is to improve patient health by expanding access to affordable medicines while pursuing sustainable operations and addressing public health challenges like non-communicable diseases.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Get referred to Viatris

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA acceptance of meloxicam NDA on May 18, 2026 with PDUFA decision December 27, 2026.
  • Greater China revenue 9.8% growth in Q1 2026 driven by cardiovascular demand and e-commerce investments.
  • New product revenues $71 million in Q1 2026 from launches including XULANE LO and meloxicam pipeline.

What critics are saying

  • EpiPen market exclusivity loss late 2026 slashes $1.2B annual revenue with 40–50% margin erosion.
  • Indore facility FDA reinspection delay beyond Q1 2027 halts $900M capacity risking $120M quarterly loss.
  • Negative ROIC of –2.6% versus 8.2% WACC destroys $1.1B shareholder value annually with no recovery moat.

What makes Viatris unique

  • Unique first approved GAD treatment Effexor SR in Japan with 7.6% patient prevalence.
  • Only global portfolio combining branded drugs, generics, complex generics, biosimilars across 165 countries.
  • Fast acting meloxicam candidate targeting 80 million acute pain patients as non-opioid alternative in US.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

18%

1 year growth

18%

2 year growth

18%
Yahoo Finance
Mar 23rd, 2026
Viatris shares surge 39.8% over past year, outpacing health care sector by 38.7%

Viatris, a global pharmaceutical company with a $15.2 billion market cap, has outperformed the broader healthcare sector despite recent headwinds. The Pennsylvania-based firm, which operates across 120 countries, has gained 39.8% over the past year, substantially ahead of the State Street Health Care Select Sector SPDR Fund's 1.1% decline. Shares have risen 10.7% over three months and 33.3% over six months, though they remain 19.9% below their 52-week high of $16.47. Viatris reported fourth-quarter revenue of $3.7 billion, up 5% year over year, with adjusted earnings per share of $0.57. Strong performance in branded drugs and emerging markets was offset by restructuring charges and pricing pressure in generics. Shares fell 5.2% following the announcement.

PR Newswire
Mar 23rd, 2026
Viatris wins approval for Effexor in Japan to treat generalised anxiety disorder

Viatris has received approval from Japan's Ministry of Health, Labour and Welfare for Effexor SR capsules to treat generalized anxiety disorder in adults, making it the first and only approved treatment for GAD in Japan. The drug was already approved in the country for major depressive disorder. The approval addresses a significant unmet need, as a recent study reported probable GAD prevalence of 7.6% in Japan's general population. The decision was based on a Phase 3 trial that demonstrated superior anxiolytic effects versus placebo at eight weeks, with all seven secondary endpoints met. Effexor was generally well tolerated with low discontinuation rates. Viatris' Japanese portfolio includes innovative products such as Spydia Nasal Spray, with several investigational therapies in development. Effexor is approved for GAD in over 80 countries worldwide.

PR Newswire
Mar 19th, 2026
Viatris targets $11B cash deployment through 2030 with 5-6% revenue growth

Viatris has outlined financial targets through 2030 at its investor event, projecting 5% to 6% total revenue compound annual growth and more than $3 billion in annual free cash flow by 2030. The pharmaceutical company's valuation at $1.45 billion reflects investor confidence in its strategic evolution. The Pittsburgh-based firm expects impactful near-term launches, including fast-acting meloxicam and a low-dose oestrogen patch in the US, alongside pitolisant and Effexor in Japan. Longer-term growth potential includes drug candidates selatogrel and cenerimod. Viatris anticipates over $11 billion in cash available for deployment through 2030, with approximately 50% allocated to business development. The company recently identified $650 million in cost savings over three years through an enterprise-wide strategic review.

Yahoo Finance
Mar 11th, 2026
Viatris shares surge 37.8% in six months, but analysts warn against buying despite cheap 5.8× P/E valuation

Viatris shares have surged 37.8% over the past six months, outpacing the S&P 500 by 34.7 percentage points, trading at $14.11. Despite the recent rally, analysts remain cautious about the pharmaceutical company's prospects. The company's fundamentals show concerning trends. Revenue grew at just 3.7% annually over the past five years, whilst earnings per share declined 9.8% annually during the same period, indicating deteriorating profitability. Most notably, Viatris posted a negative 2.6% five-year average return on invested capital, meaning management lost money whilst attempting business expansion. The stock currently trades at 5.8× forward price-to-earnings ratio. Analysts suggest the valuation appears optically cheap but warn of significant downside risk given the weak underlying fundamentals.

Yahoo Finance
Feb 26th, 2026
Viatris reports Q4 revenue of $3.7B, beating estimates by 5% with 10% growth in emerging markets

Viatris reported $3.7 billion in revenue for the quarter ended December 2025, representing a 5% year-over-year increase and beating the Zacks Consensus Estimate by 5.29%. Earnings per share reached $0.57, up from $0.54 a year ago and surpassing the consensus estimate of $0.52 by 9.62%. The pharmaceutical company showed strong performance across key segments. Greater China net sales rose 9.8% to $572.9 million, whilst Emerging Markets increased 10.1% to $564.7 million. Developed Markets generated $2.25 billion, up 4.7% year-over-year and exceeding analyst estimates. Shares of Viatris have gained 24% over the past month. The stock currently holds a Zacks Rank 3, suggesting it could perform in line with the broader market near term.